ArticleClinical rheumatology2026
TAPSE/PASP combined with IVC can identify poor prognosis in PAH patients with low and intermediate risk.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo identify echocardiographic parameters that predict prognosis in pulmonary arterial hypertension (PAH) patients with low and intermediate risk.
methodsThis single-center retrospective cohort study included PAH patients classified as low or intermediate risk according to WSPH criteria. All patients were regularly followed at the First Affiliated Hospital of Nanjing Medical University. Baseline and follow-up data were collected using standardized case report forms. Missing data were imputed using the random forest method. Statistical analyses were performed using SPSS 26.0 and R 4.3.1, with a two-sided p < 0.05 considered significant.
resultsA total of 116 PAH patients (57 low risk, 59 intermediate risk) were enrolled. During a median follow-up of 34.8 months, 28 patients (24.1%) experienced clinical failure events. The TAPSE/PASP ratio was an independent predictor of poor prognosis (HR = 0.002, 95% CI 1.09e-5-0.294, p = 0.015). Kaplan-Meier analysis showed that patients with TAPSE/PASP < 0.33 and IVC ≥ 16 mm had significantly worse event-free survival (p < 0.001).
conclusionsThe combination of TAPSE/PASP < 0.33 and IVC ≥ 16 mm identifies poor prognosis among low- and intermediate-risk PAH patients, providing a simple echocardiographic tool for early risk stratification. Key Points • TAPSE/PASP ratio combined with IVC diameter provides a simple, non-invasive index to identify poor prognosis in low- and intermediate-risk CTD-PAH patients. • This combined echocardiographic assessment may facilitate early recognition of right ventricular-pulmonary arterial uncoupling and guide timely treatment adjustment. • It refines risk evaluation beyond conventional WSPH stratification, supporting individualized long-term management in CTD-PAH.
Indexed as
Identifiers
41454200What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.